UT researchers have engineered or contributed to the development of multiple biologics aimed at addressing major unmet clinical needs in infectious diseases, cancer, genetic diseases and autoimmunity that are approved or in clinical evaluation.
-
Preclinical
SAN9-8
- RSV (respiratory syncytial virus) Anti-F plasma IgG antibody
SYN-005
- Pertussis vaccine
- Being Developed By: Synthetic Biologics, Inc.
SuperFi-Cas9
- Enzyme for genetic engineering
PEG-Chitosan
- Gene editing system
-
Clinical
HEXAPRO
- SARS-CoV-2 spike protein for Vaccine
- Being Developed By: Vaxxas (microneedle patch), PATH/Mount Sinai/Avimax (vector vaccine). Avimax completed Phase III.
IVX-241
- hMPV (human metapneumovirus) antigen
- Being Developed By: AstraZeneca
NDV-HXP-S
- SARS-CoV-2 spike protein for Vaccine
- Phase 1 in Mexico, Thailand, Brazil, Vietnam and launching Phase 1 in the U.S.
- Being Developed By: HexaPro in collaboration with PATH and Mount Sinai
AGLE-177
- Treatment of homocystinuria, metabolic disorder
- Phase 1/2
- Being Developed By: Spyre Therapeutics
AEB 1102
- Treatment of debilitating genetic disorder
- Being Developed By: Spyre Therapeutics
-
Commercial
Anthim
- Prevention of inhalational anthrax
- Being Developed By: Elusys Therapeutics
2P
- SARS-CoV-2 spike protein for Vaccine
- Being Developed By: Medigen Vaccine Biologics Corp.; Noachis Terra, Inc.; OncoSec Medical Incorporated; BioNTech AG; N4 Pharm UK Limited; Dynavax Technologies; RNAceuticals, Inc.; Sanofi Pasteur; GlaxoSmithKline Biologicals SA; Adimmune Corporation; Vaxxas Technologies; Meso Scale Diagnostics, LLC; The Binding Site Group Ltd.; ReiThera Srl; GeoVax, Inc.; ExcellGene SA; and Thermo Fisher Scientific Inc.